News

This invention relates to a proprietary recombinant metapneumovirus strain we engineered as a versatile Live-Attenuated Viral vaccine platform that can express several antigens of interest.  METAVAC® patent was exclusive licensed worldwide to Vaxxel, a spin-off of the International Research Laboratory RESPIVIR France – Canada and Virnext. Based on the METAVAC® technology, Vaxxel is developing the first intranasal bivalent vaccine candidate against human Respiratory Syncytial Virus RSV an...

Magnificent ceremony to confer the insignia of Doctor Honoris Causa of the Université Claude Bernard Lyon 1 on Guy Boivin, Full Professor of Paediatrics at the Faculté de Médecine de l'Université Laval and Microbiologist-Infectiologist at the Centre de Recherche en Infectiologie CHU de Québe – Université Laval. Under the honorary chairmanship of Olivier Dugrip, Recteur de la région académique Auvergne-Rhône-Alpes, Recteur de l'académie de Lyon, Chancelier des universités, Gabriel...

We are thrilled to present our latest newsletter, featuring the key accomplishments and scientific breakthroughs from our Technological Research Platform and its spin-offs during the 1st half of 2024. Read the English version here: https://lnkd.in/dKbmjeWKRead the French version here: https://lnkd.in/dJfYiF3A We sincerely appreciate your support and encourage you to share this update with your network....

Our study on the preclinical in vivo efficacy of Metavac®-RSV, an intranasal live-attenuated bivalent vaccine candidate against Respiratory Syncytial Virus and Human Metapneumovirus, has been published in Nature portfolio’s npj Vaccines. This study reports challenge studies performed on mice model showing that intranasal immunisation with Metavac®-RSV fully protects animals against infections with wild type HMPV and RSV, the main sources of bronchiolitis and viral pneumonia in children an...

Our spin-off Nexomis has developed a novel simulation method for generating connected differential expression signatures, based on a statistical framework that allows for adjustable levels of parametrization. This method directly addresses the issue of benchmarking data availability for connectivity-based drug repurposing approaches. This work was published in the journal Briefings in Bioinformatics (Oxford University press). It was elected article of the week by Drug Repurposing Research Collec...

We are proud to present our expertise and advancements in respiratory viral infection research using predictive in vitro human lung models.Emilie Laurent and Remi Pereira will present our latest study on SARS-CoV-2 and H1N1 Influenza infections in the AlveolAirâ„¢ model (Epithelix), in which primary human pneumocytes are co-cultured at the air-liquid interface with endothelial cells (poster session).Julien Fouret will give an oral presentation in Session 8 viral infections (June 21st) entitled Â...

Financed by the Auvergne-Rhône-Alpes Regional Innovation Fund and Bpifrance (R&D booster programme) and accredited by the Lyonbiopôle Auvergne-Rhône-Alpes health cluster, the public-private partnership program SURVIR has developed and validated an innovative automated platform for the rapid characterisation and quantification of a broad range of emerging and re-emerging respiratory pathogens. Based on a single multiplex analysis test, combined with statistical interpretation of the result...

VirNext is pleased to announce the launch of its new spin-off, Nexomis, a technological support and consultancy platform dedicated to the exploitation and enhancement of Omics data. Based on cutting-edge expertise in bioinformatics and NGS, as well as extensive skills in AI, mathematics and system administration, Nexomis is a solutions architect for computational biology. Its technological offering consists of three main services: the use of proven pipelines for rapid, high-quality analys...

We announce that the Canadian Intellectual Property Office and the European Patent Office have granted our patents for the repurposing of diltiazem as a modulator of the innate antiviral defense, and its combination with current antivirals targeting influenza viruses. The synergy between Virnext’s expertise in respiratory viruses, preclinical in vitro and in vivo infection models, and facilities, along with those of the LVMC at the Centre de recherche du CHU de Québec-Université Laval, has e...

She holds a two-year technical degree in biology and biochemical analysis, as well as a bachelor’s degree in genetic and cell biology. She is also certified to work in A1 and A2 level facilities. Romane recently graduated with a master’s degree in molecular and cellular biology with a specialization in infectiology from Université Claude Bernard Lyon 1. During her 6-month internship with our team, she studied host-virus interactions at the early stages of Respiratory Syncytial Virus infe...